Development and validation of a HPLC method for dissolution and stability assay of liquid-filled cyclosporine capsule drug products

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 959-967

  Xu, Xiaoming ^a   Gupta, Abhay ^a   Faustino, Patrick ^a   Sathe, Pradeep M ^b   Sayeed, Vilayat A ^b   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b OPS   (United States)

Author keywords

cyclosporine; degradation; dissolution; HPLC; liquid filled capsules

Indexed keywords

CYCLOSPORIN;

ANALYTIC METHOD; ARTICLE; DRUG SOLUBILITY; DRUG STABILITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; KINETICS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84890210217     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9983-8     Document Type: Article

References (18)

1. Talal N. Cyclosporine as an immunosuppressive agent for autoimmune disease: theoretical concepts and therapeutic strategies. Transplant Proc. 1988;20(3 Suppl 4):11-5.
2. D. Tedesco, L. Haragsim. Cyclosporine: a review. Journal of Transplantation 2012;230386. 2012.
3. Drugs@FDA. 2012.
4. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 1996;13(1):163-7. Springer Netherlands.
5. Friis GJ, Bundgaard H. Kinetics of degradation of cyclosporin A in acidic aqueous solution and its implication in its oral absorption. Int J Pharm. 1992;82(1-2):79-83.
6. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation. 1988;46(5):631-44.
7. Grevel J, Nuesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol. 1986;31(2):211-6.
8. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc. 2004;36(2, Supplement):S378-91.
9. Honcharik N. The effect of food on cyclosporine absorption. Selected papers from the Canadian Consensus Meeting on Cyclosporine Monitoring. Clin Biochem. 1991;24(1):89-92.
10. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107(4):631-9.
11. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res. 1989;6(1):40-3. Springer Netherlands.
12. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int. 1998;54(3):938-44.
13. Tredger JM. Using cyclosporine neoral immediately after liver transplantation. Therapeutic Drug Monitoring 1995;17[6]
14. Bowers LD, Mathews SE. Investigation of the mechanism of peak broadening observed in the high-performance liquid chromatographic analysis of cyclosporine. J Chromatogr A. 1985;333(0):231-8.
15. Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. Quality by design: understanding the product variability of a self-nanoemulsified drug delivery system of cyclosporine A. J Pharm Sci. 2007;96(9):2409-23. Wiley Subscription Services, Inc., A Wiley Company.
16. Kumar M, Singhal SK, Singh A. Development and validation of a stability indicating HPLC assay method for cyclosporine in cyclosporine oral solution USP. J Pharm Biomed Anal. 2001;25(1):9-14.
17. ICH Q2(R1) Validation of analytical procedures: text and methodology;1995.
18. Hansch C, Leo A, Hoekman DH. Exploring QSAR. Washington, DC: American Chemical Society;1995